Autolus Therapeutics falls despite AUCATZYL revenue growth, as investors focus on losses, cash burn, and cost reductions.
Stock Earnings Results
May 14, 2026
Table of Contents
May 14, 2026
Autolus Therapeutics plc (NASDAQ: AUTL) fell 12.09% after reporting first-quarter 2026 results, as investors weighed strong AUCATZYL revenue growth against continued losses, cash burn, and a cost reduction plan.
Autolus is a commercial-stage biopharmaceutical company developing and delivering programmed T cell therapies for cancer, autoimmune diseases, and neurological conditions.
The company reported AUCATZYL net product revenue of $26.2 million for the first quarter, up from $9.0 million in the prior-year period, reflecting continued U.S. launch momentum and early U.K. launch contribution.
AUCATZYL generated $26.2 million in net product revenue during the quarter.
The company said the product continued gaining market share in the U.S. for adult acute lymphoblastic leukemia, supported by physician experience and product delivery reliability. AUCATZYL also launched in the U.K. in January 2026 and is now available under routine commissioning.
Autolus reported gross profit of $1.6 million in the first quarter, compared with a gross loss in all prior quarters.
That was an important operating milestone because cell therapy businesses can struggle with manufacturing costs early in commercialization. Positive gross margin suggests the ALL business is beginning to scale more efficiently.
Autolus reported a net loss of $71.6 million, compared with a net loss of $70.2 million in the prior-year period.
Loss from operations improved to $59.5 million from $65.2 million, but SG&A expenses rose to $39.9 million as the company supported commercialization activity in the U.S. and U.K.
Autolus announced a cost reduction initiative affecting about 13% of its workforce.
The company expects the plan to reduce operating expenses by about $15 million annually beginning in 2027. It also expects about $8 million in restructuring charges, mostly tied to severance and related costs.
Autolus reiterated its full-year 2026 outlook for AUCATZYL net product revenue of $120 million to $135 million, up from $74 million in 2025.
The company also expects continued positive gross margin in 2026 and said its cash, cash equivalents, and marketable securities should fund operations into Q4 2027.
Investors are likely to watch whether Autolus can grow AUCATZYL revenue while improving margins and reducing cash burn.
The key areas are:
Autolus showed real commercial progress, but the stock reaction suggests investors wanted a clearer path to profitability.
AUCATZYL revenue grew sharply and gross margin turned positive, but losses remained high and cash declined from year-end levels. The cost reduction plan may help, but investors will need proof that revenue growth can outpace spending.
Platforms like LevelFields track earnings results, layoffs, dividends, and buybacks, helping investors identify when commercial-stage biotech stocks are moving on adoption progress versus profitability concerns.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE